Loading...
XNAS
BJDX
Market cap607kUSD
Jul 09, Last price  
1.40USD
1D
4.48%
1Q
-21.35%
IPO
-100.00%
Name

Bluejay Diagnostics Inc

Chart & Performance

D1W1MN
XNAS:BJDX chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
86.63%
Rev. gr., 5y
%
Revenues
0k
000249,040000
Net income
-7m
L-11.26%
-757,716-1,125,716-3,729,686-9,296,948-9,953,888-7,717,794-6,848,483
CFO
-6m
L-22.59%
-1,690,118-508,710-4,366,758-7,741,593-8,313,870-7,819,769-6,053,575

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
IPO date
Nov 10, 2021
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT